SOFIE retweeted
In January, we launched our iPREDICT clinical trial globally in the US, Australia, and Europe.
We are proud to announce the first patient dosed in Australia.
Read more here: imaginab.com/news-events/new…
#Australiabiotech #immunotherapy #immunooncology #clinicaltrials
SOFIE retweeted
Very excited to test the ability of a novel molecular imaging agent targeting fibroblast activated protein (FAP) to pick up pancreatic cancer!” @sofie @elcinzan @nyulangone @Perlmutter_CC #imagingpancreaticcancer prnewswire.com/news-releases…
SOFIE retweeted
Read the FDA's reasoning and remember that @NCCN and @SNM_MI guidelines support the use of other validated and FDA-approved imaging probes for PLUVICTO treatment stratification. ow.ly/i7uQ50JSg9o
#PrecisionMedicine #NucMed #ProstateCancer
SOFIE retweeted
This is your last week to submit an abstract for WMIC! Submit by July 15th, 2022.
Present your science in Miami and don't forget to book your hotel:
wmis.org/wmic1/
SOFIE retweeted
Current Issue: Fibrous Dysplasia Mimicking Skeletal Metastasis on 68Ga-FAPI PET Imaging dlvr.it/STN0Dh
FAP session at Society of Nuclear Medicine and Molecular Imaging (SNMMI) meeting attracts packed audience sofie.com/2022/06/22/fap-ses…
SOFIE retweeted
Thanks @SNM_MI for the 2022 Alavi-Mandell award for this @JournalofNucMed publication. Recognition goes to all authors. #PSMA #ProstateCancer #nuclearmedicine snmmi.org/AboutSNMMI/Content…
This quoted post is unavailable.
How perfect. Dr Gambhir would be proud.
Andrei Iagaru, MD, FACNM, has been named as the first recipient of the SNMMI Sam Gambhir Trailblazer Award. Congratulations on this honor! #SNMMI22 #NuclearMedicine
SOFIE retweeted
Impact of 18F-DCFPyL PET on Staging and Treatment of Unfavorable Intermediate or High-Risk Prostate Cancer dlvr.it/SRC7Rq
SOFIE retweeted
O. Sartor discusses the role of PSMA PET/CT for selecting patients for radioligand therapy. Thoughts? Please comment! ow.ly/aIhI50Jk05n
#MedicalImaging #PETCT #ProstateCancer @sartor_oliver
SOFIE retweeted
Predictors and Real-World Use of Prostate-Specific Radioligand Therapy: PSMA and Beyond
@asco Education Book #ASCO22
ascopubs.org/doi/full/10.120…
@DrAGafita @LouiseKostos @CalaisJeremie @pros_tic
SOFIE retweeted
We invite all WMIC 2022 attendees to fill out our pre-conference survey!
✨We want your input and feedback on WIMIN events you'd like to see at the upcoming WMIC conference. Fill out a survey & have a chance to win a $25 Amazon gift cards✨
surveymonkey.ca/r/YCRVYJT
@WMISWMIC
SOFIE retweeted
Impressive and inspiring talk by Jason Lewis @LewisLabMSKCC at the @CRUK_BI today. Jason gave us an excellent vision of the future for #PET imaging and #theranostics. Phenomenal data.
SOFIE retweeted
Also great to see 177Lu-PSMA-617 added to the NCCN guidelines. As expected post-chemo and post-ARTT. Nice speedy updates by the NCCN panel. #PSMARLT bit.ly/3LkJV2v
SOFIE retweeted
Glad to see that the NCCN agrees that either 18F-DCFPyL or 68Ga-PSMA-11 should be used for selection of patients for 177Lu-PSMA-617 radioligand therapy. Hopefully we can put this issue to rest as soon as possible! #PSMAPET - bit.ly/3LkJV2v
Our goal
To attract and retain the best people, we must redesign jobs around a simple but powerful concept: love for the content of the work itself. hbr.org/2022/05/designing-wo…
SOFIE retweeted
Look forward to seeing you all @WMISWMIC #molecular imaging #science #innovation @UCDavisResearch @LewisLabMSKCC @UCDavisCMGI @juliesut8
REMINDER: WMIC 2022 abstract deadline is next Wednesday, May 4th, 2022.
Submit your abstract: ow.ly/bxRb50ISZP6
We can't wait to see you in Miami!
